Oppenheimer Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Oppenheimer Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.5M	Buy	486,825 +1,668	+0.3%	+$97.2K	0.34%	69
2025 Q4	$26.2M	Sell	485,157 -46,381	-9%	-$2.23M	0.32%	69
2025 Q3	$24M	Buy	531,538 +32,005	+6%	+$1.49M	0.26%	87
2025 Q2	$23.1M	Sell	499,533 -4,616	-0.9%	-$227K	0.27%	90
2025 Q1	$30.7M	Buy	504,149 +15,934	+3%	+$929K	0.38%	65
2024 Q4	$27.6M	Sell	488,215 -7,018	-1%	-$392K	0.34%	70
2024 Q3	$25.6M	Buy	495,233 +27,239	+6%	+$1.28M	0.31%	75
2024 Q2	$19.4M	Buy	467,994 +111,303	+31%	+$4.98M	0.25%	93
2024 Q1	$19.3M	Sell	356,691 -18,939	-5%	-$965K	0.28%	75
2023 Q4	$19.3M	Buy	375,630 +5,350	+1%	+$281K	0.27%	81
2023 Q3	$21.5M	Buy	370,280 +1,984	+0.5%	+$122K	0.33%	63
2023 Q2	$23.6M	Buy	368,296 +6,246	+2%	+$419K	0.35%	59
2023 Q1	$25.1M	Buy	362,050 +6,437	+2%	+$454K	0.39%	58
2022 Q4	$25.6M	Buy	355,613 +4,647	+1%	+$350K	0.41%	56
2022 Q3	$24.9M	Buy	350,966 +16,917	+5%	+$1.23M	0.44%	46
2022 Q2	$25.7M	Sell	334,049 -31,444	-9%	-$2.39M	0.43%	50
2022 Q1	$26.7M	Sell	365,493 -18,125	-5%	-$1.22M	0.38%	54
2021 Q4	$23.9M	Buy	383,618 +50,301	+15%	+$2.95M	0.32%	71
2021 Q3	$19.7M	Buy	333,317 +7,942	+2%	+$523K	0.28%	80
2021 Q2	$21.7M	Buy	325,375 +64,550	+25%	+$4.21M	0.31%	68
2021 Q1	$16.5M	Sell	260,825 -20,084	-7%	-$1.25M	0.26%	92
2020 Q4	$17.4M	Buy	280,909 +34,804	+14%	+$2.14M	0.29%	80
2020 Q3	$14.8M	Buy	246,105 +18,785	+8%	+$1.13M	0.29%	83
2020 Q2	$13.4M	Buy	227,320 +17,731	+8%	+$1.06M	0.28%	88
2020 Q1	$11.7M	Buy	209,589 +2,732	+1%	+$167K	0.29%	82
2019 Q4	$13.3M	Sell	206,857 -1,379	-0.7%	-$79K	0.28%	82
2019 Q3	$10.6M	Sell	208,236 -3,025	-1%	-$142K	0.23%	100
2019 Q2	$9.58M	Buy	211,261 +5,072	+2%	+$236K	0.21%	108
2019 Q1	$9.84M	Sell	206,189 -13,384	-6%	-$667K	0.22%	110
2018 Q4	$11.4M	Buy	219,573 +7,913	+4%	+$425K	0.28%	83
2018 Q3	$13.1M	Sell	211,660 -37,419	-15%	-$2.22M	0.29%	81
2018 Q2	$13.8M	Buy	249,079 +13,297	+6%	+$718K	0.34%	74
2018 Q1	$14.9M	Buy	235,782 +5,177	+2%	+$333K	0.37%	64
2017 Q4	$14.7M	Hold	230,605	–	–	0.39%	58
2017 Q3	$14.7M	Sell	230,605 -1,771	-0.8%	-$103K	0.38%	59
2017 Q2	$12.9M	Buy	232,376 +151,105	+186%	+$8.22M	0.36%	66
2017 Q1	$4.42M	Buy	+81,271	New	+$4.46M	0.13%	188

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer Asset Management's BMY Position: Q1 2026 in Review

Oppenheimer Asset Management increased its Bristol-Myers Squibb (BMY) stake by 0.34% in Q1 2026, buying an estimated $97.2K and bringing the position to 486,825 shares worth $29.5M. The position accounts for 0.34% of the portfolio, ranked #69.

Oppenheimer Asset Management first reported a position in BMY in Q1 2017 and has held it in 37 quarters since. The position peaked at $30.7M in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Oppenheimer Asset Management held 486,825 shares of Bristol-Myers Squibb worth $29.5M as of Q1 2026.
Oppenheimer Asset Management bought 1,668 Bristol-Myers Squibb shares in Q1 2026, an estimated $97.2K.
Bristol-Myers Squibb made up 0.34% of Oppenheimer Asset Management's portfolio in Q1 2026, its #69 holding.
Oppenheimer Asset Management first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 37 quarters since.
Oppenheimer Asset Management's Bristol-Myers Squibb position peaked at $30.7M in Q1 2025.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.